BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27172795)

  • 1. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
    Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
    Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma.
    Li X; Su Y; Sun B; Ji W; Peng Z; Xu Y; Wu M; Su C
    Mol Cancer Ther; 2016 Jul; 15(7):1436-51. PubMed ID: 27196772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
    Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
    Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
    Peng W; Wu J; Feng J
    Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion, and contributes to rituximab resistance in diffuse large B-cell lymphoma.
    Liu C; Zhao X; Wang Z; Zhang C; Zheng W; Zhu X; Zhang D; Gong T; Zhao H; Li F; Guan T; Guo X; Zhang H; Yu B
    J Biol Chem; 2024 Mar; 300(3):105762. PubMed ID: 38367665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma.
    Zhu D; Fang C; Li X; Geng Y; Li R; Wu C; Jiang J; Wu C
    Oncotarget; 2017 Apr; 8(14):23228-23236. PubMed ID: 28423571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1).
    Wang Y; Guo D; Li B; Wang Y; Wang B; Wang Z; Wang M; Teng Q
    Leuk Res; 2022 Jan; 112():106769. PubMed ID: 34875555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.
    Cheng H; Yan Z; Wang X; Cao J; Chen W; Qi K; Zhou D; Xia J; Qi N; Li Z; Xu K
    Mol Cell Biochem; 2019 Nov; 461(1-2):47-56. PubMed ID: 31338678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
    Hu T; Gao Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
    Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
    Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the long non-coding RNA MALAT-1 regulated autophagy-related signaling pathway on chemotherapy resistance in diffuse large B-cell lymphoma.
    Li LJ; Chai Y; Guo XJ; Chu SL; Zhang LS
    Biomed Pharmacother; 2017 May; 89():939-948. PubMed ID: 28292022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA GAS5, as a ceRNA, inhibits the proliferation of diffuse large B‑cell lymphoma cells by regulating the miR‑18a‑5p/RUNX1 axis.
    Miao Y; Chen X; Qin M; Zhou W; Wang Y; Ji Y
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34698360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation.
    Chen CL; Tseng YW; Wu JC; Chen GY; Lin KC; Hwang SM; Hu YC
    Biomaterials; 2015 Mar; 44():71-81. PubMed ID: 25617127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100.
    Shu L; Guo K; Lin ZH; Liu H
    J Clin Lab Anal; 2022 Jan; 36(1):e24168. PubMed ID: 34888946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Shi X; Cui Z; Liu X; Wu S; Wu Y; Fang F; Zhao H
    Biochem Biophys Res Commun; 2019 Mar; 510(4):594-600. PubMed ID: 30739786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma.
    Zhu FQ; Zeng L; Tang N; Tang YP; Zhou BP; Li FF; Wu WG; Zeng XB; Peng SS
    Oncol Res; 2016 Oct; 24(6):415-427. PubMed ID: 28281962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
    Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
    Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.